Literature DB >> 25348012

Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.

Luciano G Martelotto1, Charlotte Ky Ng, Maria R De Filippo, Yan Zhang, Salvatore Piscuoglio, Raymond S Lim, Ronglai Shen, Larry Norton, Jorge S Reis-Filho, Britta Weigelt.   

Abstract

BACKGROUND: Massively parallel sequencing studies have led to the identification of a large number of mutations present in a minority of cancers of a given site. Hence, methods to identify the likely pathogenic mutations that are worth exploring experimentally and clinically are required. We sought to compare the performance of 15 mutation effect prediction algorithms and their agreement. As a hypothesis-generating aim, we sought to define whether combinations of prediction algorithms would improve the functional effect predictions of specific mutations.
RESULTS: Literature and database mining of single nucleotide variants (SNVs) affecting 15 cancer genes was performed to identify mutations supported by functional evidence or hereditary disease association to be classified either as non-neutral (n = 849) or neutral (n = 140) with respect to their impact on protein function. These SNVs were employed to test the performance of 15 mutation effect prediction algorithms. The accuracy of the prediction algorithms varies considerably. Although all algorithms perform consistently well in terms of positive predictive value, their negative predictive value varies substantially. Cancer-specific mutation effect predictors display no-to-almost perfect agreement in their predictions of these SNVs, whereas the non-cancer-specific predictors showed no-to-moderate agreement. Combinations of predictors modestly improve accuracy and significantly improve negative predictive values.
CONCLUSIONS: The information provided by mutation effect predictors is not equivalent. No algorithm is able to predict sufficiently accurately SNVs that should be taken forward for experimental or clinical testing. Combining algorithms aggregates orthogonal information and may result in improvements in the negative predictive value of mutation effect predictions.

Entities:  

Mesh:

Year:  2014        PMID: 25348012      PMCID: PMC4232638          DOI: 10.1186/s13059-014-0484-1

Source DB:  PubMed          Journal:  Genome Biol        ISSN: 1474-7596            Impact factor:   13.583


  38 in total

Review 1.  Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data.

Authors:  Gregory M Cooper; Jay Shendure
Journal:  Nat Rev Genet       Date:  2011-08-18       Impact factor: 53.242

Review 2.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Computational approaches to identify functional genetic variants in cancer genomes.

Authors:  Abel Gonzalez-Perez; Ville Mustonen; Boris Reva; Graham R S Ritchie; Pau Creixell; Rachel Karchin; Miguel Vazquez; J Lynn Fink; Karin S Kassahn; John V Pearson; Gary D Bader; Paul C Boutros; Lakshmi Muthuswamy; B F Francis Ouellette; Jüri Reimand; Rune Linding; Tatsuhiro Shibata; Alfonso Valencia; Adam Butler; Serge Dronov; Paul Flicek; Nick B Shannon; Hannah Carter; Li Ding; Chris Sander; Josh M Stuart; Lincoln D Stein; Nuria Lopez-Bigas
Journal:  Nat Methods       Date:  2013-08       Impact factor: 28.547

4.  Genetic interactions in cancer progression and treatment.

Authors:  Alan Ashworth; Christopher J Lord; Jorge S Reis-Filho
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582

Review 5.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

6.  Identifying cancer driver genes in tumor genome sequencing studies.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2010-12-17       Impact factor: 6.937

7.  Identifying Mendelian disease genes with the variant effect scoring tool.

Authors:  Hannah Carter; Christopher Douville; Peter D Stenson; David N Cooper; Rachel Karchin
Journal:  BMC Genomics       Date:  2013-05-28       Impact factor: 3.969

8.  Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models.

Authors:  Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt
Journal:  Hum Mutat       Date:  2012-11-02       Impact factor: 4.878

9.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

Review 10.  Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.

Authors:  Crispin Hiley; Elza C de Bruin; Nicholas McGranahan; Charles Swanton
Journal:  Genome Biol       Date:  2014-08-27       Impact factor: 13.583

View more
  64 in total

1.  The genetic landscape of endometrial clear cell carcinomas.

Authors:  Deborah F DeLair; Kathleen A Burke; Pier Selenica; Raymond S Lim; Sasinya N Scott; Sumit Middha; Abhinita S Mohanty; Donavan T Cheng; Michael F Berger; Robert A Soslow; Britta Weigelt
Journal:  J Pathol       Date:  2017-09-05       Impact factor: 7.996

2.  Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Authors:  Zhiqiang Li; Pedram Razavi; Qing Li; Weiyi Toy; Bo Liu; Christina Ping; Wilson Hsieh; Francisco Sanchez-Vega; David N Brown; Arnaud F Da Cruz Paula; Luc Morris; Pier Selenica; Emily Eichenberger; Ronglai Shen; Nikolaus Schultz; Neal Rosen; Maurizio Scaltriti; Edi Brogi; Jose Baselga; Jorge S Reis-Filho; Sarat Chandarlapaty
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

3.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

4.  The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Authors:  Caterina Marchiò; Felipe C Geyer; Charlotte Ky Ng; Salvatore Piscuoglio; Maria R De Filippo; Marco Cupo; Anne M Schultheis; Raymond S Lim; Kathleen A Burke; Elena Guerini-Rocco; Mauro Papotti; Larry Norton; Anna Sapino; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-12-26       Impact factor: 7.996

5.  Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.

Authors:  Amber M Bates; Emily A Lanzel; Fang Qian; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-05-25

6.  MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.

Authors:  Salvatore Piscuoglio; Melissa Murray; Nicola Fusco; Caterina Marchiò; Florence L Loo; Luciano G Martelotto; Anne M Schultheis; Muzaffar Akram; Britta Weigelt; Edi Brogi; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2015-05-24       Impact factor: 5.087

7.  Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.

Authors:  Jason E Duex; Kalin E Swain; Garrett M Dancik; Richard D Paucek; Charles Owens; Mair E A Churchill; Dan Theodorescu
Journal:  Mol Cancer Res       Date:  2017-10-02       Impact factor: 5.852

8.  Predicting pathogenicity of missense variants with weakly supervised regression.

Authors:  Yue Cao; Yuanfei Sun; Mostafa Karimi; Haoran Chen; Oluwaseyi Moronfoye; Yang Shen
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

9.  Comparison and optimization of in silico algorithms for predicting the pathogenicity of sodium channel variants in epilepsy.

Authors:  Katherine D Holland; Thomas M Bouley; Paul S Horn
Journal:  Epilepsia       Date:  2017-05-18       Impact factor: 5.864

10.  Uterine adenosarcomas are mesenchymal neoplasms.

Authors:  Salvatore Piscuoglio; Kathleen A Burke; Charlotte K Y Ng; Anastasios D Papanastasiou; Felipe C Geyer; Gabriel S Macedo; Luciano G Martelotto; Ino de Bruijn; Maria R De Filippo; Anne M Schultheis; Rafael A Ioris; Douglas A Levine; Robert A Soslow; Brian P Rubin; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2015-12-28       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.